Effect of cannabis use on PTSD treatment outcomes in veterans
- PMID: 34316419
- PMCID: PMC8287864
- DOI: 10.9740/mhc.2021.07.238
Effect of cannabis use on PTSD treatment outcomes in veterans
Abstract
Introduction: Researchers have found anandamide (an endocannabinoid) and cannabinoid type 1 receptor activation encourages extinction of aversive memories. Some theorize cannabinoids such as those in cannabis may provide a new treatment approach for PTSD, while others suggest it may worsen symptomology. The objective of the current study was to determine if cannabis use impacts the success of evidence-based intensive outpatient PTSD treatment in a veteran population.
Methods: A list of veterans enrolled in the Battle Creek Veterans' Affairs Medical Center outpatient PTSD Clinical Team Clinic between October 1st, 2008 and October 1st, 2016 was obtained, and a random sample was identified. Study participants were veterans aged 18 to 85 years, with at least 2 PTSD Checklist scores, and a diagnosis of PTSD. Data collected included mental health medications, type and number of evidence-based psychotherapy used, and presence of co-occurring behavioral health diagnoses. The cannabis use group was compared to the no-cannabis-use group, and differences in variables pertaining to the relative number of treatment successes and failures was evaluated for statistical and clinical significance.
Results: The majority of patients were white (87.1%) and male (95%). The success rate was similar between the cannabis and no-cannabis-use groups (51.9% and 51.4%, respectively).
Discussion: The current study did not show that a predominantly white male veteran sample diagnosed with PTSD differed in intensive PTSD treatment success or failure based on cannabis use.
Keywords: PTSD; cannabis; posttraumatic stress disorder; trauma.
© 2021 CPNP. The Mental Health Clinician is a publication of the College of Psychiatric and Neurologic Pharmacists.
Conflict of interest statement
Disclosures: The authors have no financial or other disclosures to report.
Figures
References
-
- Freitas HR, Isaac AR, Malcher-Lopes R, Diaz BL, Trevenzoli IH, De Melo Reis RA. Polyunsaturated fatty acids and endocannabinoids in health and disease. Nutr Neurosci. 2018;21(10):695–714. DOI: 10.1080/1028415X.2017.1347373 PubMed PMID: 28686542. - DOI - PubMed
-
- Neumeister A, Normandin MD, Pietrzak RH, Piomelli D, Zheng MQ, Gujarro-Anton A, et al. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry. 2013;18(9):1034–40. DOI: 10.1038/mp.2013.61 PubMed PMID: 23670490. - DOI - PMC - PubMed
-
- Atakan Z. Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol. 2012;2(6):241–54. DOI: 10.1177/2045125312457586 PubMed PMID: 23983983 PubMed Central PMCID: PMC3736954. - DOI - PMC - PubMed
-
- Niesink RJM, van Laar MW. Does cannabidiol protect against adverse psychological effects of THC? Front Psychiatry. 2013;4:130. DOI: 10.3389/fpsyt.2013.00130 PubMed PMID: 24137134 PubMed Central PMCID: PMC3797438. - DOI - PMC - PubMed
-
- Fraser GA. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD) CNS Neurosci Ther. 2009;15(1):84–8. DOI: 10.1111/j.1755-5949.2008.00071.x PubMed PMID: 19228182 PubMed Central PMCID: PMC6494011. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources